…
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Avenue Therapeutics is a specialty pharmaceutical company developing an intravenous tramadol formulation for management of moderate-to-severe acute pain in adults. Long-term growth drivers include achieving regulatory approval and commercial launch of its lead product candidate and potential uptake in surgical and emergency settings seeking IV analgesics with lower abuse profiles than stronger opioids. The company may appeal to investors interested in a focused pipeline targeting an addressable acute-pain market if clinical and regulatory milestones are achieved.
Key investment risks include regulatory and clinical outcome uncertainty, limited cash and the need for additional financing, competition from established analgesics and generics, and commercialization and reimbursement challenges.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -2.95M | -11.70M | -10.49M | -3.60M | -3.73M |
| Minority interest | 0.04M | 0.04M | 0.11M | 0.05M | - |
| Net income | -2.91M | -11.65M | -10.38M | 2.05M | -3.72M |
| Selling general administrative | 3.65M | 4.64M | 4.18M | 5.34M | 2.48M |
| Selling and marketing expenses | - | - | 4.17M | - | - |
| Gross profit | 1.40M | - | - | - | - |
| Ebit | - | - | -10.49M | -8.04M | -3.74M |
| Ebitda | -3.29M | -11.70M | 4.05M | -8.02M | -3.74M |
| Depreciation and amortization | - | - | 14.54M | 0.02M | 0.01M |
| Operating income | -3.29M | -11.28M | -14.54M | -8.04M | -3.74M |
| Other operating expenses | 4.69M | 11.28M | 14.54M | 8.04M | 3.74M |
| Interest expense | - | 0.00M | 0.33M | 1.16M | 0.01M |
| Interest income | 0.12M | 0.18M | 0.13M | 0.02M | 0.01M |
| Net interest income | 0.12M | 0.18M | -0.21M | -1.14M | 0.01M |
| Income tax expense | - | - | -0.11M | -5.65M | -0.01M |
| Total revenue | 1.40M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 4.69M | 11.28M | 14.54M | 8.04M | 3.74M |
| Total other income expense net | 0.34M | -0.41M | 4.05M | 4.44M | 0.01M |
| Net income from continuing ops | -2.95M | -11.70M | -10.49M | -3.60M | -3.73M |
| Net income applicable to common shares | - | - | - | - | -3.73M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2.93M | 2.67M | 1.85M | 6.84M | 3.96M |
| Other current assets | 0.08M | 0.08M | 0.07M | 0.14M | 0.11M |
| Total liab | 1.10M | 0.82M | 1.20M | 3.58M | 0.51M |
| Total stockholder equity | 1.83M | 2.80M | 1.58M | 3.90M | 3.45M |
| Other current liab | 1.10M | 0.66M | 0.80M | 2.61M | 0.15M |
| Common stock | - | - | 0.00M | - | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -105.49M | -102.58M | -90.93M | -80.55M | -77.00M |
| Other assets | 0.08M | 0.08M | 0.07M | 0.00M | - |
| Cash | 2.85M | 2.59M | 1.78M | 6.71M | 3.76M |
| Total current liabilities | 1.10M | 0.82M | 1.20M | 3.58M | 0.51M |
| Net debt | -2.85M | -2.59M | -1.78M | -6.71M | -3.76M |
| Other stockholder equity | 107.32M | 105.38M | 92.51M | 84.46M | 80.45M |
| Total current assets | 2.85M | 2.67M | 1.85M | 6.84M | 3.96M |
| Net tangible assets | - | - | - | - | 3.45M |
| Net receivables | - | - | - | - | 0.09M |
| Inventory | - | - | - | - | 0.11M |
| Accounts payable | 0.09M | 0.15M | 0.40M | 0.97M | 0.36M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | -3.00M | - | 0.00M |
| Change to liabilities | - | - | - | 0.35M | -0.38M |
| Total cashflows from investing activities | - | - | -3.00M | - | - |
| Total cash from financing activities | 2.09M | 9.84M | 7.53M | 10.54M | 4.38M |
| Change to operating activities | - | - | - | -0.03M | -0.08M |
| Net income | -2.91M | -11.70M | -10.38M | -3.60M | -3.73M |
| Change in cash | 0.26M | 0.81M | -4.92M | 2.94M | 0.63M |
| Begin period cash flow | 2.59M | 1.78M | 6.71M | 3.76M | 3.13M |
| End period cash flow | 2.85M | 2.59M | 1.78M | 6.71M | 3.76M |
| Total cash from operating activities | -1.83M | -9.03M | -9.45M | -7.60M | -3.75M |
| Issuance of capital stock | 2.09M | 1.62M | 7.53M | 12.01M | 5.04M |
| Other cashflows from investing activities | - | - | -3.00M | - | - |
| Change to account receivables | - | - | - | 0.09M | -0.09M |
| Sale purchase of stock | -0.00M | - | 1.23M | -1.10M | - |
| Other cashflows from financing activities | 2.09M | 8.21M | 0.00M | -0.36M | -0.66M |
| Change to netincome | - | - | - | -4.45M | 0.44M |
| Capital expenditures | 0.00M | 0.00M | 3.00M | 0.00M | 0.00M |
| Change in working capital | 0.30M | 0.18M | -0.29M | 0.41M | -0.46M |
| Stock based compensation | 0.67M | 1.24M | 0.91M | 0.65M | 0.44M |
| Other non cash items | 0.11M | 1.25M | 0.31M | -5.05M | 4.19M |
| Free cash flow | -1.83M | -9.03M | -12.45M | -7.60M | -3.75M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ATXI Avenue Therapeutics Inc |
- -% |
0.30 | - | 17.99 | 1.50 | 1.03 | -0.42 |
| NVO Novo Nordisk A/S |
0.04 0.09% |
38.91 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.97 1.15% |
526.63 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
9.17 0.99% |
932.51 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develops BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is headquartered in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
781 652 4500
1
| Name | Title | Year Born |
|---|---|---|
| Dr. Lindsay Allan Rosenwald | Exec. Chairman | 1955 |
| Dr. Xiaoqin Lu M.D. | Consultant | 1975 |
| Dr. Alexandra MacLean M.D. | Chief Exec. Officer | 1967 |
| Mr. David Jin | Interim CFO, COO & Corp. Sec. | 1990 |
| Dr. Scott A. Reines M.D., Ph.D. | Interim Chief Medical Officer | 1947 |
| Srinivas Subramanian | Exec. VP | NA |
| Dr. Alexandra MacLean M.D. | CEO & Director | 1968 |
| Mr. David Jin | Interim CFO, COO & Corporate Secretary | 1991 |
| Dr. Lindsay Allan Rosenwald | Executive Director | 1955 |
| Mr. Srinivas Subramanian | Executive Vice President | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.